MDMB-CHMINACA

File:MDMB-CHMINACA.svg

MDMB-CHMINACA.svg

MDMB-CHMINACA is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the cannabinoid receptors, specifically the CB1 receptor and CB2 receptor. MDMB-CHMINACA is structurally related to other synthetic cannabinoids such as AB-FUBINACA and ADB-CHMINACA.

Chemical Structure

MDMB-CHMINACA belongs to the indazole-3-carboxamide family. Its chemical name is Methyl 2-[[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate. The compound features a cyclohexylmethyl group attached to the indazole core, which is a common structural motif in many synthetic cannabinoids.

Pharmacology

MDMB-CHMINACA acts as a potent agonist at the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system. This system plays a crucial role in regulating various physiological processes including pain sensation, appetite, mood, and memory. The activation of these receptors by MDMB-CHMINACA can lead to psychoactive effects similar to those produced by tetrahydrocannabinol (THC), the primary active component of cannabis.

Legal Status

The legal status of MDMB-CHMINACA varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. For example, in the United States, it is listed as a Schedule I substance under the Controlled Substances Act.

Health Risks

The use of MDMB-CHMINACA has been associated with numerous adverse health effects. These can include tachycardia, hypertension, nausea, vomiting, hallucinations, and seizures. In severe cases, it can lead to acute kidney injury and death. The variability in the potency and purity of synthetic cannabinoids like MDMB-CHMINACA further increases the risk of adverse effects.

Detection in Biological Samples

MDMB-CHMINACA and its metabolites can be detected in biological samples such as urine and blood using techniques like liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS). These methods are essential for forensic and clinical toxicology to confirm exposure to the substance.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system
• Designer drug